AIS Biotech

AIS Biotech (with AIS for Anti Infective Sugar) is a French Biotech company based in the Alps incorporated in March 2023 with the objective of developing a new class of anti-infective biotherapies.

AIS Biotech is dedicated to the development of Innovative sugar-based biotherapies to fight against (re)emerging infectious diseases and Antimicrobial Resistance (AMR).

Thanks to a sustainable Bioengineering plateform based on the expertise of a leading edge academic laboratory (CERMAV, CNRS, Grenoble FRANCE), AIS Biotech aims to develop a pipeline of innovative sugar-based anti-infective biopharmaceuticals.

By mimicking the natural host surface oligosaccharide binding-sites of pathogens, our compounds act as decoy receptors to prevent or treat the infection.

GlycoFlu, our first drug-candidate is developed to prevent and treat infection by human Influenza viruses, a global public health concern with a large socio-economic impact.